✦ LIBER ✦

Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell Malignancy

✍ Scribed by Quanzhi Li; Wendy Hudson; Duo Wang; Erica Berven; Fatih M. Uckun; John H. Kersey

Publisher: Springer-Verlag
Year: 1998
Tongue: English
Weight: 349 KB
Volume: 47
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s002620050512

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti-CD3-based bispecific antibody desig

Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms

✍ Brian K. Link; Sheri A. Kostelny; Michael S. Cole; William P. Fusselman; J. Yun 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 107 KB 👁 2 views

## Anti -CD3 ؋ anti-B-cell antigen bispecific monoclonal antibodies (bsAbs) can redirect T-cell-mediated lysis toward malignant B cells. Clinical trials with CD3-based bsAbs have shown toxicity in patients which is likely related to nonspecific T-cell activation and targeting. Our current studies

Synergistic cytotoxicity of iodine-131-a

Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas

✍ Timothy A. Johnson; Oliver W. Press 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 231 KB

Preliminary clinical trials suggest that iodine-131 ( 131 I)labeled anti-CD20 monoclonal antibodies (MAbs) are effective single agents for the treatment of relapsed non-Hodgkin's B-cell lymphomas. However, despite high initial response rates, most patients treated in this manner will eventually rela

T-cell-mediated lysis of B cells induced

T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent

✍ Michael Gruen; Kurt Bommert; RalfC. Bargou 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 363 KB

In situ expression of B7 and CD28 recept

In situ expression of B7 and CD28 receptor families in human malignant melanoma: Relevance for T-cell-mediated anti-tumor immunity

✍ Ralf W. Denfeld; Andrea Dietrich; Christiane Wuttig; Eszter Tanczos; Johannes M. 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 977 KB

Work in animal models has suggested that interactions of members of the 87 receptor family (e.g., 87-I, 87-2) on tumor cells with their ligands CD28 and CTLA-4 on cytotoxic T cells (CTL) are important for the induction of anti-tumor immunity against malignant melanoma (MM). To determine whether thes

Evaluation of four CD22 antibodies as ri

Evaluation of four CD22 antibodies as ricin a chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas

✍ Guo-Liang Shen; Jia-Ling Li; Maria-Ana Ghetie; Victor Ghetie; Richard D. May; Ma 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 French ⚖ 668 KB

Ricin A chain-containing immunotoxins (IT-As) specific for the human &ell antigen, CD22, were prepared from 4 monoclonal antibodies (MAbs) or their Fab' fragments: RFB4, HD6, UV22-I and UV22-2. The ITS were tested for their ability to kill cells from the Burkitt lymphoma line, Daudi, the pre-6cell l

Peptide-antibody conjugates for tumour t

Peptide-antibody conjugates for tumour therapy: A MHC-class-II-restricted tetanus toxin peptide coupled to an anti-IG light chain antibody can induce cytotoxic lysis of a human B-cell lymphoma by specific CD4 T cells

✍ Zhiwei Yu; Frank Healy; Danila Valmori; Patricia Escobar; Giampietro Corradin; J 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 729 KB

Anti-idiotype antibody therapy of B-cell lymphomas, despite numerous promising experimental and clinical studies, has so far met with limited success. Tailor-made monoclonal antiidiotype antibodies have been injected into a large series of lymphoma patients, with a few impressive complete tumour rem